PHVS Key Statistics, Chart & Performance
The current stock price of PHVS is 24.04 USD. In the past month the price increased by 6.23%. In the past year, price increased by 30.65%.
PHVS Latest News, Press Relases and Analysis
PHVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.67 | 928.57B | ||
| JNJ | JOHNSON & JOHNSON | 19.26 | 481.76B | ||
| MRK | MERCK & CO. INC. | 11 | 240.48B | ||
| PFE | PFIZER INC | 7.92 | 144.02B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.72 | 103.11B | ||
| ZTS | ZOETIS INC | 18.26 | 51.01B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.27 | 21.99B | ||
| VTRS | VIATRIS INC | 4.8 | 12.89B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.28 | 10.15B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.49 | 8.75B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.32B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.20B |
Related stock screener links
About PHVS
Company Profile
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 108 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Company Info
PHARVARIS NV
Emmy Noetherweg 2
Leiden ZUID-HOLLAND NL
CEO: Berndt Modig
Employees: 114
Phone: 31712036410
PHARVARIS NV / PHVS FAQ
Can you describe the business of PHARVARIS NV?
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 108 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Can you provide the latest stock price for PHARVARIS NV?
The current stock price of PHVS is 24.04 USD. The price decreased by -5.17% in the last trading session.
What is the dividend status of PHARVARIS NV?
PHVS does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHVS stock?
PHVS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for PHARVARIS NV?
PHARVARIS NV (PHVS) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of PHVS stock?
PHARVARIS NV (PHVS) has a market capitalization of 1.54B USD. This makes PHVS a Small Cap stock.
What is the outstanding short interest for PHARVARIS NV?
The outstanding short interest for PHARVARIS NV (PHVS) is 1.13% of its float.
PHVS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PHVS. When comparing the yearly performance of all stocks, PHVS is one of the better performing stocks in the market, outperforming 82.98% of all stocks.
PHVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHVS. While PHVS seems to be doing ok healthwise, there are quite some concerns on its profitability.
PHVS Financial Highlights
Over the last trailing twelve months PHVS reported a non-GAAP Earnings per Share(EPS) of -3.4. The EPS decreased by -12.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.31% | ||
| ROE | -52.43% | ||
| Debt/Equity | 0 |
PHVS Forecast & Estimates
18 analysts have analysed PHVS and the average price target is 45.73 USD. This implies a price increase of 90.22% is expected in the next year compared to the current price of 24.04.